Biotech Stock Mailbag Readers' Portfolio
BOSTON (TheStreet) -- It's time to introduce the Biotech Stock Mailbag Readers' Portfolio.
My request for your favorite 2010 biotech stock picks brought in nominations for 93 different stocks. I'm really pleased with the response, so thanks to everyone who participated.
I decided to narrow down the list of nominees to a manageable portfolio of 20 stocks. These reader-suggested stocks will form the basis of the Biotech Stock Mailbag Readers' Portfolio (BSMRP), which I'll update and write about regularly throughout the year.
Let's take a closer look at the stocks that make up the BSMRP.
Of the 93 stocks submitted, ten received three or more votes, so they were immediately seated into the portfolio. ImmunoGen (IMGN) received the most recommendations, with seven votes total. Curis (CRIS), Allos Therapeutics (ALTH) and Ariad Pharmaceuticals (ARIA) each received four votes. Six stocks received three votes each: GenVec (GNVC), Vertex Pharmaceuticals (VRTX), Vivus (VVUS), StemCells (STEM), Spectrum Pharmaceuticals (SPPI) and Mannkind (MNKD). My job became a bit trickier when deciding how to fill the remaining ten portfolio slots, which needed to come from the 20 stocks that received two votes apiece from readers.Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
